Describe the template used for normalization/transformation, specifying subject space or group standardized space (e.g. original Talairach, MNI305, ICBM152) OR indicate that the data were not normalized.
Reply to 'Currently available bulk sequencing data do not necessarily support a model of neutral tumor evolution'
Werner et al. reply -In their correspondence, McDonald et al. 1 question our assertion that the distribution of mutations in tumor bulk sequencing data suggests an underlying neutral evolutionary process in a proportion of cancers 2 and instead propose alternative explanations that incorporate subclonal selection. We agree with the authors' demonstration that it is possible, in principle, to construct models of selection that produce patterns similar to the neutral model. However, the key issue is whether the proposed models of selection are realistic, meaningful and, most importantly, more appropriate than the null neutral model. Before examining this issue, we first note that we extensively stressed in the original manuscript 2 that the majority of cases we examined were not consistent with neutral evolution (~70% appeared non-neutral), and we did specifically cite Gerlinger et al. 3 as an example of data dominated by selection 2 . Our finding that the majority of cancers do show evidence of subclonal selection is consistent with previous literature, including the cases highlighted by McDonald et al. 3, 4 . Arguably, clonal evolution results from the interplay of three fundamental processes: random alterations (genetic, epigenetic, etc.), random drift and nonrandom selection, the third of which is the most complex to define and model. In the established field of population genetics, extensive effort has been dedicated to modeling the first two processes without selection, the so-called neutral dynamics [5] [6] [7] . This includes the development of entire statistical frameworks based on neutrality, such as coalescent theory 8 . On the contrary, models that include selection, especially in growing populations, have been much harder to derive analytically owing to the large number of assumptions in the definition of selection, including whether selection is clone intrinsic or clone extrinsic (microenvironmentally defined) and whether the magnitude of selection is constant or fluctuates in response to population dynamics. Importantly, most models of selection describe cancer dynamics in terms of time 9, 10 (for example, time to fixation of a selected mutant) and therefore, although insightful, are hard to apply to cancer genomic data where temporal dynamics are often unobservable.
In light of this complexity, in our study, we asked the simple question of what happens to the mutations in a growing tumor in the case where only the first two processes above, namely random mutations and drift, are operating. This leads to a relatively simple model that is analytically tractable, wherein subclonal mutations accumulate following a 1/f cumulative distribution 2 . We note that this is the underlying solution of the fully stochastic Luria-Delbrück model, as previously demonstrated 11, 12 . Importantly, this model is based on the 'null hypothesis' of molecular evolution in cancer [13] [14] [15] and predicts what the absence of subclonal selection should look like in a growing tumor. We tested this hypothesis against subclonal mutations from a large body of sequencing data and found that in about 30% of cases we could not reject this null hypothesis, at least within the resolution of the currently available data.
In their correspondence, McDonald et al. 1 propose a more complex scenario that includes ongoing selection and report that in some cases their model also fits the 1/f cumulative distribution. First, we examine the fit of their proposed model to the data and highlight that considering the stochastic nature of selected mutants would change the interpretation of their analysis. Second, we discuss the distinction between evaluating the power of a test and the limitations of the information content in the data to which the test is applied, in this case singlesample bulk sequencing. Third, we analyze the plausibility of the authors' biological assumptions underlying their model. In the correspondence by McDonald et al.
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, neutrality was correctly rejected in a considerable proportion of simulations with subclonal selection (R 2 < 0.98; their Fig. 1b) . The exact proportion of cases incorrectly classified as neutral is not reported, but a few specific examples are shown in their Fig. 1c-f . Importantly, in those cases, the mutant proportion at the time of sampling is not reported nor is the time when the mutant was introduced. Both are key factors in judging the strength of the selection signal for two reasons: (i) in the case of strong and early selection, wherein a selected mutant sweeps to fixation, the evolutionary dynamics revert to neutral, and hence accepting the null for the final tumor is correct (as all cells in the tumor bear the selected mutation, so there is no subclonal selection) and (ii) because of the inherent stochasticity of the evolutionary process, selected mutants can either occur too late to grow to a detectable size or be weakly selected such that the clonal population of the tumor remains virtually unchanged with respect to the neutral expectation. Judging from Fig. 2a , this seems to be what happens often: most mutants have fitness slightly higher than 1 (where 1 is neutral) and many have fitness even lower than 1 (should be negatively selected), but all persist in the population. In such a model, it is clear that selection is not sculpting the population by removing unfit clones and benefitting fitter ones, as any mutant-fit or unfit-seems to survive. Thus, the dynamics described in the models of McDonald et al. 1 are 'effectively neutral' , and relatedly, it is not surprising that deviations from neutrality are undetectable.
We highlight that it is fundamentally important to consider the size of differentially selected subclones when considering whether or not a tumor can be classified as neutrally evolving. In the authors' second simulation model (their Fig. 2 ), many clones arise very late and are therefore undetectable in the data (high frequency of red dots representing a clone size of one cell in their Fig. 2a) . We argue that no test will ever be able to detect a subclone made of a single cell in a whole malignancy-and indeed, it is debatable whether a clone of size 1 can even be considered to have been selected. We discuss the detection limits imposed by current data in our original manuscript (Fig. 5) 
2
, as well as in subsequent work 16, 17 .
To demonstrate the impact of subclone size in determining whether a tumor is classified as (effectively) neutral or not, we performed a more thorough analysis of our previous model of a stochastic branching process under selection ( Fig. 1 in this letter) . These simulations show that, in the presence of a subclone of detectable size in the data (for example, one that is not too small to be out of the detectable range of the variant allele frequency (VAF) distribution and has not swept through the whole tumor), the 1/f test is powered to reject neutrality (1/f test calculated over the frequency range [0.05-0.5] of subclonal mutations from simulated diploid tumors; Fig. 1 ).
McDonald et al. 1 also suggest that improved fits to a 1/f distribution are found in larger populations, irrespective of the underlying model. This assertion is based on the three individual examples presented in Fig. 2b ,c, but appears to be contradicted by their Fig. 2d , which summarizes the results of 25 simulations across different selection regimes; in this panel, no difference in the distribution of goodness-of-fit values is evident between small and large tumors (no tests of significance were reported). Aside from this, the frequency interval for inferences is also changed 20-fold between realizations of their models (Fig. 2b ,c,e), making comparisons difficult.
In general, we agree with the authors' suggestion that R 2 values are not the optimal measurement of fit for a cumulative distribution. Moreover, we note that a limitation of the 1/f statistical test is sensitivity to the choice of integration range in the VAF distribution. To be optimal, the 1/f test should be applied only to subclonal mutations and the whole detectable frequency spectrum should be used (for example, for ~100× sequencing depth, from a minimum of 5% to a maximum of 50% VAF in a diploid tumor; Fig. 1 ). We note that in follow-up work we have developed more sensitive tests, as well as a Bayesian model selection method that uses the whole VAF distribution to directly compare neutrality versus selection 17 . Our original threshold of R 2 < 0.98 to reject neutral evolution as an explanation for the data was ad hoc but based on an estimation of the variability in the cumulative VAF due to stochasticity in the neutral evolution process together with the stochasticity caused by library preparation and moderate-depth sequencing.
Next, we consider key biological assumptions of the models proposed by McDonald et al. 1 . Both models include a strong assumption that almost all mutations affect fitness. In the first scenario (their Fig. 1a ), all mutations increase fitness in an additive manner, implying that all mutations in a tumor would be categorized as 'drivers' . This would include noncoding mutations (> 98% of all mutations in a cancer genome) and even synonymous variants (~25% of all exonic mutations). This assumption is at odds with what is currently known about the human genome and with a whole body of evidence from large-scale cross-sectional genomic studies that have identified a relatively small number of driver alterations 18 among a large number of passengers 19 . Consequently, we think this is an implausible assumption. Furthermore, recognizing that most point mutations in cancer genomes are passengers is key to performing subclonal analysis from bulk samples 20, 21 , as it is the increase in frequency of passenger mutations hitchhiking within a selected mutant that allows the detection of subclones.
A second questionable assumption of the presented subclonal selection models is that of infinite improvement. In this model, populations evolve by climbing a fitness slope, leading to linear evolution. The 'fitness landscape' interpretation has now replaced this model 22 , wherein fitness is defined by a complex landscape of peaks and valleys corresponding to distinct phenotypes in the population, and is consistent with clonal evolution as well 23 . We note that some of the authors of the correspondence by McDonald et al. 1 have recently rejected an infinite improvement model as unsupported by the data in their interesting recent publication 24 . In summary, we argue that, if the data are equally consistent with the simple mechanistic null model, incorporating cell division, cell death, mutation and absence , where we could either model a neutral evolutionary process or a process whereby a selected subclone reaches a certain proportion, or cancer cell fraction (CCF), in the tumor. We chose parameters in our model that matched the characteristics of our TCGA colon cancer cohort, namely that we observe around 300 mutations per exome per sample. Simulation parameters: mutation rate = 8 mutations per division, cellularity = 1, ploidy = 2, read depth = 100× , birth rate = ln(2), death rate = ln(2)/2. To implement selection, a cell at a random time t event is given a random selection coefficient s, which either decreases the death rate or increases the birth rate. We ran 1,000 neutral simulations, and for simulations with selected subclones we ran 1,000 simulations for each of the following resultant subclone CCFs: (i) 0.1 < CCF < 0.9, (ii) 0.2 < CCF < 0.8 and (iii) 0.3 < CCF < 0. of selection, and a complex model of selection, then by Occam's razor we should not reject the null in favor of the complex alternative. Thus, when faced with only a 1/f distribution as evidence, we think it would be a fallacy to assume that the complex rather than the neutral model produced it.
We do agree, however, that it is paramount to recognize the limitations of currently available data. Specifically, singlesample bulk sequencing data at moderate depth are intrinsically limited in capturing the subclonal evolutionary dynamics and intratumoral heterogeneity of a tumor. To better measure evolutionary dynamics in cancer, we emphasize the need for better data, such as extremely deep sequencing, multi-region sampling and, ultimately, single-cell point mutation sequencing.
code availability
Simulation code is available at https://github. com/marcjwilliams1/neutral-tumourevolution-werner-2018. To the Editor -Tumors arise as a result of evolutionary processes operating on somatic cells within tissues, and thus identifying the modes of cancer evolution is of fundamental interest. In an analysis of whole-exome-and whole-genomesequencing data for 904 samples from 14 different cancer types and cohorts, Williams et al. 1 have reported that the mutant-allele frequencies of approximately one-third (323/904) of the samples follow a simple power-law distribution (mean R 2 ~0.90-0.98 for each cohort) and have inferred that subclones in those tumors are under neutral evolution. In that study, the authors used mutant-allele frequency from whole-genome-and whole-exomesequencing data as a direct proxy for the relative fraction of tumor cells carrying that mutation, and they fitted the power law directly to the distributions of mutant-allele-frequency estimates. This procedure can introduce different types of biases. Various steps of the genomic pipeline including tumor-DNA extraction, PCR amplification, and sequencing protocols introduce variability 2 , such that allelic proportional read counts do not automatically indicate clonal proportion and instead follow a distribution with the underlying clonal proportion as a prior in diploid regions. Additional variation in allele-frequency estimates could arise because of copy number alterations and pathological tumor purity. Williams et al. 1 selected only high-purity tumors (≥ 70%), and analyzed regions with copy number absolute log R ratio ≤ 0.5, but these filters were lenient, and purity and ploidy estimates were not explicitly included in the model. As we show below, these attributes can collectively contribute to a moderate level of overdispersion of the allele-frequency distribution of somatic mutations and present challenges in fitting the power-law distribution.
Analyzing copy number and exomesequencing data for > 300 paired tumornormal samples from The Cancer Genome Atlas (TCGA) 3 bladder, lung, and colon cancers, and focusing on the genomic regions with absolute log R ratio ≤ 0.5 (details in Supplementary Methods), we observed that most of the samples had greater dispersion in the read-count-based allelic-frequency distribution of germline SNPs in the tumor genomes than in the matched normal genomes. This result is partly due to low-allele-frequency somatic subclonal copy number events (for example, absolute log R ratio ≤ 0.5) in the tumor genomes (Fig. 1a,b) . We then examined the effects of the dispersion of the somatic allele-frequency distribution in tumor genomes on the power-law fit. Following an established approach 4 , we fitted a beta-binomial model to the allele-frequency distributions of germline variants to the TCGA samples to account Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see Authors & Referees and the Editorial Policy Checklist.
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When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main text, or Methods section).
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The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided
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Mycoplasma contamination
Confirm that all cell lines tested negative for mycoplasma contamination OR describe the results of the testing for mycoplasma contamination OR declare that the cell lines were not tested for mycoplasma contamination.
Commonly misidentified lines (See ICLAC register)
Name any commonly misidentified cell lines used in the study and provide a rationale for their use.
Palaeontology Specimen provenance
Provide provenance information for specimens and describe permits that were obtained for the work (including the name of the issuing authority, the date of issue, and any identifying information).
Specimen deposition
Indicate where the specimens have been deposited to permit free access by other researchers. 
Dating methods

ChIP-seq Data deposition
Confirm that both raw and final processed data have been deposited in a public database such as GEO.
Confirm that you have deposited or provided access to graph files (e.g. BED files) for the called peaks. 
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Flow Cytometry Plots
Confirm that:
The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
All plots are contour plots with outliers or pseudocolor plots.
A numerical value for number of cells or percentage (with statistics) is provided.
Methodology Sample preparation
Describe the sample preparation, detailing the biological source of the cells and any tissue processing steps used.
Instrument
Identify the instrument used for data collection, specifying make and model number.
Software
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